Governance & Functioning

Governance and Functioning

The Directorate


Pierre Laurent-Puig is oncology Professor at the Paris Descartes University Medical School (PDUMS). Since 2004, he is also director of the INSERM laboratory U1147 (former 775) “Medicine, Pharmacogenomics and Therapeutic Optimization” at Paris Descartes University. He works within the Department of Biology at the European Georges Pompidou Hospital Paris, where he is responsible for the Clinical Oncogenetic Unit. He is the scientific director of Cancéropôle Île-de-France.

“The three research projects developed thin the CARPEM are in close relation. The CARPEM will allow important progress in personalized medicine by integrating genetical, immulological and ethical dimensions. By gathering the different research teams, this project carried by AP-HP has a unique capacity to favour the transfer from personalized medicine to clinical practice and make it a reality for those suffering from cancer”. Pr Pierre Laurent-Puig (WebZine of APHP)

Michaëla Fontenay is Professor of Hematology at Paris Descartes University – Medical School and responsible of the Laboratory of Biological Hematology of “Hôpitaux Universitaires Paris Centre”.
Her research activities focused on the pathophysiology of myelodysplastic syndromes within the Inserm unit U1016 in the team “Normal and pathological hematopoïesis” at Cochin Institut.

PR WOLF-HERVÉ FRIDMAN: CARPEM deputy director Wolf-Hervé Fridman emeritus Professor of immunology at Paris Descartes University Medical School and President of Cancéropôle Île-de-France since 2014. In 2007, He created the “Centre de Recherche des Cordeliers”. After being responsible for clinical immunology unit at Institut Curie from 1987 to 2000, he joined the Hôpital Européen Georges-Pompidou in 2000 to manage the Immunology Department.

Administrative governance

The administrative governance of CARPEM project is handled by Aurore Hattabi for the scientific coordination and Agnès Casi for the administrative and financial side.

Yannick Ladeiro, PhD: CARPEM Secretary General

After completing his PhD in liver tumor genomics in Jessica Zucman-Rossi’s laboratory, Yannick Ladeiro joined Eric Ogier-Denis’ team to work on chronic inflammatory bowel disease. He then joined Inception Sciences in order to set up an annex of this American drug development company in Paris. At the end of this mission, he trained in project management in a start-up company (Design Your Cube) by organizing the world’s largest Rubik’s Cube competition and by validating a university course at Centrale Lille. He then led and coordinated the HTE program (Cancer Plan 2014-2019) alongside Jessica Zucman-Rossi before joining CARPEM in early 2020.

Sandrine Pham, PhD: CARPEM Scientific Coordinator

Graduated as a medical laboratory technician, Sandrine joined in 2013 the team “Cell Cycle and Liver physiopathology” at the Cochin Institute as an assistant engineer. She then decided to pursue her university education with the SVT program at the Ecole Pratique des Hautes Etudes (EPHE), and chose to complete her course with a PhD on liver metabolic diseases. She then joined the EPHE and the team Microbiota, Intestines, Inflammation at the Saint Antoine Research Center as a lecturer, before joining the SIRIC CARPEM team at the end of 2021.

Agnès Casi: Administrative and financial manager of CARPEM

After 17 years in the private sector in France and Quebec, Agnès Casi also worked in higher education for a few years in the Research Department of the University of Paris Dauphine-PSL, working closely with research centers and research teachers. Agnès Casi has acquired solid experience in administrative and budgetary management, HR management and project engineering. Also sensitive to the world of the Arts, Agnès Casi has been practicing the flute at the Conservatory and remains a great nostalgic of Claude Sautet’s movies.

The Scientific organization

Steering Committee

The Director and Deputy Directors together with the Secretary General and the Scientific Coordinator manage the Steering Committee. It gathers ones a month and defines the scientific strategy, the financial management of the CARPEM as well as all the items that might have an incidence on the management of the CARPEM. Structure of the Committee :

  • Patients representatives: Patrice Marvanne & Marion Lanly
  • Coordinators of the 3 integrated research programs of the CARPEM

– Program 1 : Metabolism, Genetics, Immunity & Environment (Jessica Zucman-Rossi ,Guido Kroemer)

– Program 2 : Cancer heterogeneity related to tumor and host diversity for patient management (Valerie Taly, Eric Tartour)

– Program 3 : Dynamic consent and health democracy in CARPEM (Marie-France Mamzer, Mathilde Touvier)

CARPEM Council

The CARPEM Council under the chairmanship of the Director is informed of all key events in the life of the CARPEM. The Director presents and discusses the CARPEM budget, changes in structures and personnel, new participating research teams and changes in the scientific CARPEM strategy. The CARPEM Council can make recommendations as to any subject that has been brought to debate. The members of the Council are:

  • Clinical team leaders:
  1. Digestive cancer (Julien Taïeb, Romain Coriat)
  2. Lung cancer (Marco Alifano, Françoise Le Pimbec-Barthes)
  3. Endocrine cancer (Jérôme Bertherat, Anne-Paule Gimenez Roqueplo)
  4. Urologic cancer (Arnaud Mejean, Stéphane Oudard)
  5. Gynecological cancer (Fabrice Lécuru, Jérôme Alexandre)
  6. ENT cancer (Pierre Bonfils)
  7. Hematological cancer (Didier Bouscary, Olivier Hermine)
  8. Medical Oncology (François Goldwasser, Stéphane Oudard)
  9. Radiotherapy (Catherine Durdux)
  10. Nutrition (Sébastien Czernichow)
  11. Oncogeriatry (Elena Paillaud)
  • Leaders of the 21 research teams:
  1. Personalized Medicine, Pharmacogenomics and optimization therapeutic (Pierre Laurent-Puig)
  2. Functional genomics of solid tumors (Jessica Zucman-Rossi)
  3. Genetics of pheochromocytomas and paragangliomas (PHEO and PGL) (Anne-Paule Gimenez Roqueplo)
  4. Immunotherapy and antiangiogenic therapy in oncology (Eric Tartour)
  5. Imaging of angiogenesis and its metabolic consequences (Olivier Clément)
  6. Laboratory of integrative cancer immunology (Jérôme Galon)
  7. Apoptosis cancer and immunity (Guido Kroemer)
  8. Immune microenvironment and cancer (Catherine Sautés-Fridman)
  9. Endocrine tumors and signaling (Jérôme Bertherat)
  10. Oxidative stress, inflammation and cellular proliferation (Frédérique Batteux)
  11. Normal and Pathological Hematopoiesis (Michaëla Fontenay, Didier Bouscary)
  12. Oncogenesis of digestive epithelium (Christine Perret, Béatrice Romagnolo)
  13. Lymphocyte activation and immunological synapse (Emmanuel Donnadieu, Clothilde Randriamampita)
  14. Hematology and Pathology – Normal and pathological lymphoïd differenciation (Olivier Hermine, Elisabeth Macintyre)
  15. Medical Ethics (Marie-France Mamzer)
  16. Computational Epi-Genetics of cancer (Valentina Boeva)
  17. Proliferation, stress and liver physiopathology (Chantal Desdouet)
  18. Methods of therapeutic evaluation of chronic diseases (Philippe Ravaud)
  19. Nutritional epidemiology (Mathilde Touvier)
  20. Information Sciences to support Personalized Medicine (Anita Burgun)
  21. Metabolic diseases and comorbidities (Fabienne Foufelle)
  22. Oncogenic functions of beta-catenin signalling in the liver (Sabine colnot)
  •   Leaders of the platforms:
  1. Translational Research Platform & Data warehouse
  2. Genomic
  3. Proteomics 3P5
  4. Animal housing/Small animal imaging
  5. Pharmaceutics and Toxicology
  6. Biobanks
  7. Vaccinal immunomonitoring
  8. Tumor microenvironnement


The CARPEM can rely on a Scientific Advisory Board (SAB) composed of nine leading experts in cancer:

  • Ana Anderson
  • Lucy Godley
  • Michael Karin
  • Josef Penninger
  • Alain Puisieux
  • Arnaud Roth
  • Robert Schreiber
  • Frank Sinicrope
  • Ma’n Zawati

They offer their scientific expertise, critical opinion and strategic research advice, as well as their worldwide recognition. The first board took place on 6th July 2013 and the second the 11th January 2016. During the second CARPEM accreditation, the scientific council met on February 20, 2020.

SAB REPORT July 2013

SAB REPORT January 2016

SAB REPORT February 2020


Initially, two separate and multidisciplinary committees were established at CARPEM:
  • an interdisciplinary experts committee
  • a patients committee.
In January 2016, the CARPEM decided to merge the two committees into one: ATEB (Advisory Translational Ethics Board), gathering patients, patients’ representatives and professionals together with ethicists. This ATEB meets quarterly and functions as an advisory board overseeing the ethical and cultural dimensions of all CARPEM projects. It will raise any ethical issues that might emerge during the process of translational research. It is composed of :
  • 6 patients’ representatives
  • 3 members of the research teams of CARPEM
  • 3 representatives of the laboratory of medical ethics
Its role is to advise the steering committee in any actions needed to improve the project in terms of ethics, information, and returned results to the patients. It allows scientists to understand challenges that they are facing in their research projects and to provide better understanding to patients. It is also the witness of the appropriation of CARPEM project by the patients.